Literature DB >> 10679924

PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer.

W Dai1, Y Li, B Ouyang, H Pan, P Reissmann, J Li, J Wiest, P Stambrook, J L Gluckman, A Noffsinger, P Bejarano.   

Abstract

The human PRK gene encodes a protein serine/threonine kinase of the polo family and plays an essential role in regulating meiosis and mitosis. We have previously shown that PRK expression is downregulated in a significant fraction of lung carcinomas. Our current studies reveal that PRK mRNA expression is downregulated in a majority (26 out of 35 patients) of primary head and neck squamous-cell carcinomas (HNSCC) compared with adjacent uninvolved tissues from the same patients, regardless of stage. In addition, PRK transcripts were undetectable in one of the two HNSCC cell lines analyzed. Ectopic expression of PRK, but not a PRK deletion construct, in transformed A549 fibroblast cells suppresses their proliferation. Furthermore, fluorescence in situ hybridization analyses show that the PRK gene localizes to chromosome band 8p21, a region that exhibits a high frequency of loss of heterozygosity in a variety of human cancers, including head and neck cancers, and that is proposed to contain two putative tumor suppressor genes. Considering that PRK plays an important role in the regulation of the G2/M transition and cell cycle progression, our current studies suggest that deregulated expression of PRK may contribute to tumor development. Genes Chromosomes Cancer 27:332-336, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679924     DOI: 10.1002/(sici)1098-2264(200003)27:3<332::aid-gcc15>3.0.co;2-k

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

Review 2.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.

Authors:  Kazim Sahin; Mehmet Tuzcu; Mehmet Yabas; Cemal Orhan; Nurhan Sahin; Ibrahim H Ozercan
Journal:  Invest New Drugs       Date:  2017-11-15       Impact factor: 3.850

Review 4.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

5.  Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity.

Authors:  Qi Wang; Suqing Xie; Jie Chen; Kenji Fukasawa; Ulhas Naik; Frank Traganos; Zbigniew Darzynkiewicz; Meena Jhanwar-Uniyal; Wei Dai
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

Review 6.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

7.  Dysregulation of the polo-like kinase pathway in CD4+ T cells is characteristic of pathogenic simian immunodeficiency virus infection.

Authors:  Pavel Bostik; Geraldine L Dodd; Francois Villinger; Ann E Mayne; Aftab A Ansari
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice.

Authors:  Alejandra Ward; Alan Morettin; David Shum; John W Hudson
Journal:  BMC Cancer       Date:  2011-02-15       Impact factor: 4.430

9.  Mitotic Kinases and p53 Signaling.

Authors:  Geun-Hyoung Ha; Eun-Kyoung Yim Breuer
Journal:  Biochem Res Int       Date:  2012-07-19

10.  Roles of Polo-like kinase 3 in suppressing tumor angiogenesis.

Authors:  Dazhong Xu; Qi Wang; Yongping Jiang; Yanxi Zhang; Eleazar Vega-Saenzdemiera; Iman Osman; Wei Dai
Journal:  Exp Hematol Oncol       Date:  2012-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.